Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 208

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Alteration in gut microbiota associated with hepatitis B and non-hepatitis virus related hepatocellular carcinoma

Open access
Liu, Qisha, Li, Fan, Zhuang, Yaoyao, Xu, Jian, Wang, Jianwei, Mao, Xuhua, Zhang, Yewei, Liu, Xingyin · 2019 · Gut Pathogens

Abstract

The onset of hepatocellular carcinoma (HCC) ranked fifth malignancies all over the world. Increasing evidences showed that the distribution of HCC was related to the incidence of chronic hepatitis B virus (HBV) infection and other factors, such as alcoholism, aflatoxin B1 ingestion and obesity. Recent studies demonstrated that gut dysbiosis plays an important role in liver diseases. However, the researches on gut microbiota of HBV and non-HBV non-HCV related HCC have not been reported. In this study, we investigated the differences between the gut microbiota of HBV related HCC (B-HCC) and non-HBV non-HCV related HCC (NBNC-HCC), finally found some potential bacteria, linking different pathological mechanism of both types of HCCs. We carried out 16S rRNA analyses in a cohort of 33 healthy controls, 35 individuals with HBV related HCC (B-HCC) and 22 individuals with non-HBV non-HCV (NBNC) related HCC (NBNC-HCC). We found that the species richness of fecal microbiota of B-HCC patients was much higher than other two groups. Interestingly, the feces of NBNC-HCC patients harbored more potential pro-inflammatory bacteria ( Escherichia - Shigella , Enterococcus ) and reduced levels of Faecalibacterium , Ruminococcus , Ruminoclostridium which results in decrease potential of anti-inflammatory short-chain fatty acids. The feces of NBNC-HCC patients had relatively fewer abundance of multiple biological pathways related to amino acid and glucose metabolism, but high level of transport and secretion in some types. However, the B-HCC patients had opposite results of bacterial composition and associated multiple biological pathways versus NBNC-HCC patients. Meanwhile, we found that aberrant network of gut microbiota occurred differently in B-HCC and NBNC-HCC patients. Our study indicated that B-HCC and NBNC-HCC patients showed differential abundance of bacteria involved in different functions or biological pathways. We suggested the modification of specific gut microbiota may provide the therapeutic benefit for B-HCC and NBNC-HCC.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13099-018-0281-6

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 18 references

Research works printed but not linked: 38

  1. Tu T, Budzinska MA, Maczurek AE, Cheng R, Di BA, Warner FJ, et al. Novel aspects of the liver microenvironment in hepatocellular carcinoma pathogenesis and development. Int J Mol Sci. 2014;15:9422–58. · DOI
  2. Elserag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012;142:1264–73. · DOI · Paper page
  3. Tsai KN, Kuo CF, Ou JJ. Mechanisms of hepatitis B virus persistence. Trends Microbiol. 2017;26:33–42. · DOI · Paper page
  4. Khetrapal SP. Towards ending viral hepatitis as a public health threat: translating new momentum into concrete results in South-East Asia. Gut Pathog. 2018;10:9. · doi:10.1186/s13099-018-0237-x
  5. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat. 2004;11:97–107. · DOI · Paper page
  6. Betrapally NS, Gillevet PM, Bajaj JS. Gut microbiome and liver disease. Transl Res. 2017;179:49–59. · DOI
  7. Wang J, Wang Y, Zhang X, Liu J, Zhang Q, Zhao Y, et al. Gut microbial dysbiosis is associated with altered hepatic functions and serum metabolites in chronic hepatitis B patients. Front Microbiol. 2017;8:2222. · DOI · Paper page
  8. Woodhouse CA, Patel VC, Singanayagam A, Shawcross DL. Review article: the gut microbiome as a therapeutic target in the pathogenesis and treatment of chronic liver disease. Aliment Pharmacol Ther. 2018;47:1–11. · doi:10.1111/apt.14295
  9. Bajaj JS, Hylemon PB, Ridlon JM, Heuman DM, Daita K, White MB, et al. Colonic mucosal microbiome differs from stool microbiome in cirrhosis and hepatic encephalopathy and is linked to cognition and inflammation. Am J Physiol-Gastr L. 2012;303:675–85.
  10. Chen Y, Yang F, Lu H, Wang B, Chen Y, Lei D, et al. Characterization of fecal microbial communities in patients with liver cirrhosis. Hepatology. 2011;54:562–72. · DOI · Paper page
  11. Lu H, Wu Z, Xu W, Yang J, Chen Y, Li L. Intestinal microbiota was assessed in cirrhotic patients with hepatitis B virus infection. Microb Ecol. 2011;61:693–703. · DOI · Paper page
  12. Fukui H. Gut microbiome-based therapeutics in liver cirrhosis: basic consideration for the next step. J Clin Transl Hepatol. 2017;5:249–60.
  13. Clark DP. The fermentation pathways of Escherichia coli. FEMS Microbiol Rev. 1989;5:223.
  14. Willemsen LE, Koetsier MA, van Deventer SJ, van Tol EA. Short chain fatty acids stimulate epithelial mucin 2 expression through differential effects on prostaglandin E(1) and E(2) production by intestinal myofibroblasts. Gut. 2003;52:1442–7. · DOI · Paper page
  15. Wang HB, Wang P, Wang X, Wan YL, Liu YC. Butyrate enhances intestinal epithelial barrier function via up-regulation of tight junction protein Claudin-1 transcription. Dig Dis Sci. 2012;57:3126–35. · DOI · Paper page
  16. Sokol H, Pigneur B, Watterlot L, Lakhdari O, Bermúdezhumarán LG, Gratadoux JJ, et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci USA. 2008;105:16731–6. · DOI · Paper page
  17. Liu J. Ethanol and liver: recent insights into the mechanisms of ethanol-induced fatty liver. World J Gastroenterol. 2014;20:14672. · DOI
  18. Meng J, Wang Q, Liu K, Yang S, Fan X, Liu B, et al. Systemic and splanchnic lipopolysaccharide and endothelin-1 plasma levels in liver cirrhosis before and after transjugular intrahepatic portosystemic shunt. Gastroent Res Pract. 2016;2016:1–5.
  19. Jiang W, Wu N, Wang X, Chi Y, Zhang Y, Qiu X, et al. Dysbiosis gut microbiota associated with inflammation and impaired mucosal immune function in intestine of humans with non-alcoholic fatty liver disease. Sci Rep. 2015;5:8096. · DOI · Paper page
  20. Bei R, Mizejewski GJ. Alpha fetoprotein is more than a hepatocellular cancer biomarker: from spontaneous immune response in cancer patients to the development of an AFP-based cancer vaccine. Curr Mol Med. 2011;11:564–81. · doi:10.2174/156652411800615162
  21. Ogata H, Fujibuchi W, Goto S, Kanehisa M. A heuristic graph comparison algorithm and its application to detect functionally related enzyme clusters. Nucleic Acids Res. 2000;28:4021. · DOI · Paper page
  22. Chen Y, Nan Q, Jing G, Qian G, Fang D, Ding S, et al. Functional gene arrays-based analysis of fecal microbiomes in patients with liver cirrhosis. BMC Genomics. 2014;15:753. · DOI
  23. Xu M, Wang B, Fu Y, Chen Y, Yang F, Lu H, et al. Changes of fecal Bifidobacterium species in adult patients with hepatitis B virus-induced chronic liver disease. Microb Ecol. 2012;63:304–13. · DOI
  24. Ashraf R, Shah NP. Immune system stimulation by probiotic microorganisms. Crit Rev Food Sci Nutr. 2014;54:938–56. · DOI · Paper page
  25. Nugent JL, Mccoy AN, Addamo CJ, Wei J, Sandler RS, Keku TO. Altered tissue metabolites correlate with microbial dysbiosis in colorectal adenomas. J Proteome Res. 2014;13:1921–9. · DOI
  26. Kosumi K, Hamada T, Koh H, Borowsky J, Bullman S, Twombly TS, et al. The amount of bifidobacterium genus in colorectal carcinoma tissue in relation to tumor characteristics and clinical outcome. Am J Pathol. 2018;188:2839–52. · DOI
  27. Abdou RM, Zhu L, Baker RD, Baker SS. Gut microbiota of nonalcoholic fatty liver disease. Dig Dis Sci. 2016;61:1268–81. · DOI
  28. Wei X, Yan X, Zou D, Yang Z, Wang X, Liu W, et al. Abnormal fecal microbiota community and functions in patients with hepatitis B liver cirrhosis as revealed by a metagenomic approach. BMC Gastroenterol. 2013;13:1–8. · DOI
  29. Ferrari C. HBV and the immune response. Liver Int. 2015;35:121–8. · DOI · Paper page
  30. Katz SC, Burga RA, Mccormack E, Wang LJ, Mooring JW, Point G, et al. Phase I hepatic immunotherapy for metastases study of intra-arterial chimeric antigen receptor modified T cell therapy for CEA+ liver metastases. Clin Cancer Res. 2015;21:3149–59. · DOI · Paper page
  31. Zhang Q, Zhang Z, Peng M, Fu S, Xue Z, Zhang R. CAR-T cell therapy in gastrointestinal tumors and hepatic carcinoma: from bench to bedside. Oncoimmunology. 2016;5:e1251539. · DOI
  32. Gao H, Li K, Tu H, Pan X, Jiang H, Shi B, et al. Development of T cells redirected to glypican-3 for the treatment of hepatocellular carcinoma. Clin Cancer Res. 2014;20:6418–28. · DOI · Paper page
  33. Zhu J, Zhang T, Cao L, Li A, Zheng K, Zhang N, et al. Toll like receptor7 polymorphisms in relation to disease susceptibility and progression in Chinese patients with chronic HBV infection. Sci Rep. 2017;7:12417. · DOI
  34. Okamura Y, Sugiura T, Ito T, Yamamoto Y, Ashida R, Uesaka K. The impact of the hepatitis B core antibody status on recurrence in patients with Non-B Non-C hepatocellular carcinoma after curative surgery. Dig Surg. 2017;35:243–51. · DOI
  35. Li Y, Fan J, Wang B, Lu L, Shi J, Niu J, et al. Guidelines for management of nonalcoholic fatty liver disease: an updated and revised edition. J Clin Hepatol. 2010;15:229–32.
  36. Hoffmann J. Stapler transection of the oesophagus for bleeding oesophageal varices. Scand J Gastroenterol. 1983;18:707–11. · doi:10.3109/00365528309182084
  37. Durand F, Valla D. Assessment of the prognosis of cirrhosis: child-Pugh versus MELD. J Hepatol. 2005;42:S100–7. · DOI · Paper page
  38. Braak CJFT, Smilauer P. CANOCO reference manual and canodraw for windows user’s guide: software for canonical community ordination (version 4.5). Ithaca: Microcomputer Power; 2002.

Cited by

See all 208

Metadata

Authors
Liu, Q., Li, F., Zhuang, Y., Xu, J., Wang, J., Mao, X., Zhang, Y., & Liu, X.
Venue
Gut Pathogens
Published
2019-01-18
Volume
11
Issue
1
Pages
1-1
ISSN
1757-4749 (ISSN-L)
OpenAlex
W2918180541
Cited by
208
References
18
FWCI
7.81
Type
journal article
Language
en
Open access
gold
Licence
creativecommons.org/licenses/by/4.0/ (tdm)
Funders
  • Natural Science Foundation of Jiangsu Province (BK20161025, BK20161572)
  • Nanjing Medical University (2015NJMUZD014)
  • National Natural Science Foundation of China (81671983)
  • 33 Program for High Level Talents of Jiangsu Province (BRA2016508)
  • Six Talent Peaks Project in Jiangsu Province (WSW041)
  • Key Medical Subjects of Jiangsu Province (2016KJQWZDRC-03)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Alteration in gut microbiota associated with hepatitis B and non-hepatitis virus related hepatocellular carcinoma. https://app.cochat.ai/papers/10.1186/s13099-018-0281-6
The paper
Liu, Q., Li, F., Zhuang, Y., Xu, J., Wang, J., Mao, X., Zhang, Y., & Liu, X. (2019). Alteration in gut microbiota associated with hepatitis B and non-hepatitis virus related hepatocellular carcinoma. Gut Pathogens. https://doi.org/10.1186/s13099-018-0281-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.